Navigating the New Frontier: The Impact of Joint Clinical Assessments on Regulatory Affairs

As the pharmaceutical landscape evolves, the emergence of Joint Clinical Assessments (JCAs) in the EU and Inflation Reduction Act (IRA) in the US marks a significant shift in how new therapies are evaluated and approved. This session will delve into the transformative impact of JCAs on regulatory affairs and market access teams within pharmaceutical development & manufacturing.

Join industry experts and regulatory professionals as we explore the challenges and opportunities presented by this new regulatory framework. Attendees will gain insights into the increased need for coordination with health technology assessment bodies, the strategic planning required to navigate the JCA process, and the enhanced data preparation necessary to meet the rigorous standards of multiple jurisdictions.

Through case studies and interactive discussions, we will examine best practices for engaging with stakeholders, including patient groups and clinical experts, to ensure comprehensive and robust clinical data submissions. Additionally, we will discuss the potential benefits of JCAs, such as streamlined processes and improved patient access to innovative treatments, as well as the resource-intensive nature of this new approach.

This session is essential for regulatory affairs and market access professionals seeking to stay ahead in a rapidly changing environment. Equip yourself with the knowledge and strategies needed to successfully manage the complexities of JCAs and drive your organization's success in the global market.